Chris Abbosh is a Senior Director at Astrazeneca working in translational medicine. Chris is a physician and trained as a fellow under Professor Charles Swanton in London on the lung TRACERx project. During that time he became interested in use of ctDNA as a minimal residual disease biomarker in non-small-cell lung cancer, working with the teams who developed Signatera and Archer PCM. This work formed the basis of Chris's PhD and led to multiple publications including a first author paper in Nature and patents related to technology development. Chris came to Astrazeneca motivated by translation of cutting-edge science into novel clinical trial designs and biomarkers to improve treatment selection for patients suffering with cancer.

Dr. Estelamari Rodriguez is Associate Director of Community Outreach and Co-Lead of the Thoracic Site Disease Group of the NCI-designated Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine. She has a special interest in the early phase clinical trials and is an active member of the Experimental Therapeutics Program at Sylvester Comprehensive Cancer Center.

C2i Genomics deploys an innovative ctDNA MRD solution for personalized cancer detection and monitoring. C2i’s whole-genome technology provides ultra-high sensitivity with significantly reduced lab operation complexity, eliminate the need to develop a patient-specific assay, and allowing earlier detection of recurrent cancer, to inform better treatment decisions and improve outcomes.

Merck KGaA, Darmstadt, Germany is a science-led organization dedicated to making a meaningful difference in the lives of people affected by cancer. Our oncology research aims to leverage our synergistic portfolio to tackle challenging tumor types, as we work to illuminate a path to scientific breakthroughs to transform patient outcomes. Learn more at www.merckgrouponcology.com

Signatera is a personalized, tumor-informed ctDNA assay for molecular residual disease (MRD) detection and treatment response monitoring in patients previously diagnosed with cancer. Signatera is optimized to detect low levels of ctDNA, to help stratify high risk patients and optimize patient management. Discover more at: www.natera.com/oncology/signatera-advanced-cancer-detection/

Sermonix Pharmaceuticals Inc is a privately held biopharmaceutical company with a precision medicine focus for bringing targeted oncology products through development, approval, and commercialization. Sermonix’s Lasofoxifene, entering phase 3, is thought to be a potent
third-generation selective estrogen receptor modulator (SERM) with high affinity for the estrogen receptor 1 (ESR1).